Statement: In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial.
Primary_evidence: Adverse Events 1:   Total: 7/42 (16.67%)   Febrile neutropenia 1/42 (2.38%)   Left venrticular dysfunction 1/42 (2.38%)   Cardiac valve disease 1/42 (2.38%)   Diarrhoea 0/42 (0.00%)   Abdominal pain 1/42 (2.38%)   Colitis 0/42 (0.00%)   Nausea 0/42 (0.00%)   Vomiting 0/42 (0.00%)   Pyrexia 0/42 (0.00%)   Influenza like illness 1/42 (2.38%)   Oedema peripheral 1/42 (2.38%)   Fatigue 0/42 (0.00%) Adverse Events 2:   Total: 7/42 (16.67%)   Febrile neutropenia 0/42 (0.00%)   Left venrticular dysfunction 1/42 (2.38%)   Cardiac valve disease 0/42 (0.00%)   Diarrhoea 0/42 (0.00%)   Abdominal pain 0/42 (0.00%)   Colitis 0/42 (0.00%)   Nausea 0/42 (0.00%)   Vomiting 0/42 (0.00%)   Pyrexia 2/42 (4.76%)   Influenza like illness 0/42 (0.00%)   Oedema peripheral 0/42 (0.00%)   Fatigue 0/42 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 21/209 (10.05%)   Anaemia 0/209 (0.00%)   Febrile neutropenia 0/209 (0.00%)   Thrombocytopenia 0/209 (0.00%)   Acute myocardial infarction 0/209 (0.00%)   Cardiac failure 0/209 (0.00%)   Diplopia 0/209 (0.00%)   Gastric haemorrhage 0/209 (0.00%)   Nausea 0/209 (0.00%)   Oral pain 0/209 (0.00%)   Vomiting 1/209 (0.48%)   Mucosal inflammation 0/209 (0.00%)   Pain 1/209 (0.48%) Adverse Events 2:   Total: 29/216 (13.43%)   Anaemia 2/216 (0.93%)   Febrile neutropenia 2/216 (0.93%)   Thrombocytopenia 2/216 (0.93%)   Acute myocardial infarction 1/216 (0.46%)   Cardiac failure 1/216 (0.46%)   Diplopia 1/216 (0.46%)   Gastric haemorrhage 1/216 (0.46%)   Nausea 1/216 (0.46%)   Oral pain 2/216 (0.93%)   Vomiting 2/216 (0.93%)   Mucosal inflammation 1/216 (0.46%)   Pain 0/216 (0.00%)